Our findings provide novel insights into the underlying pathogenesis of LUAD. CTNNA2 mutation can change the immune microenvironment, thereby improving patient prognosis. The results also suggest that CTNNA2 may become a new biomarker and therapeutic target for LUAD in the future. READ ARTICLE
Frontiers in Pharmacology DOI: 10.3389/fphar.2021.645862
Authors: Wen Y., Lin A., Zhu W., Wei T., Luo P., Guo L. and Zhang J.
Read More